WallStSmart

CareCloud Inc. (CCLD)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 46853% more annual revenue ($56.58B vs $120.50M). NVS leads profitability with a 23.9% profit margin vs 9.0%. CCLD appears more attractively valued with a PEG of 0.31. CCLD earns a higher WallStSmart Score of 64/100 (C+).

CCLD

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 7.0Value: 8.0Quality: 7.0
Piotroski: 5/9Altman Z: 2.39

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCLDUndervalued (+74.9%)

Margin of Safety

+74.9%

Fair Value

$8.92

Current Price

$3.02

$5.90 discount

UndervaluedFair: $8.92Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCLD5 strengths · Avg: 9.0/10
PEG RatioValuation
0.3110/10

Growing faster than its price suggests

EPS GrowthGrowth
5739.0%10/10

Earnings expanding 5739.0% YoY

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.9%8/10

Revenue surging 21.9% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

CCLD2 concerns · Avg: 3.5/10
P/E RatioValuation
30.5x4/10

Premium valuation, high expectations priced in

Market CapQuality
$129.60M3/10

Smaller company, higher risk/reward

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCLD

The strongest argument for CCLD centers on PEG Ratio, EPS Growth, Debt/Equity. Revenue growth of 21.9% demonstrates continued momentum. PEG of 0.31 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : CCLD

The primary concerns for CCLD are P/E Ratio, Market Cap.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

CCLD profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

CCLD carries more volatility with a beta of 1.83 — expect wider price swings.

CCLD is growing revenue faster at 21.9% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

CCLD scores higher overall (64/100 vs 51/100) and 21.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CareCloud Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. The company is headquartered in Somerset, New Jersey.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?